Tag: PD-L1 inhibitor for MIBC

Home / PD-L1 inhibitor for MIBC

Categories

Durvalumab is approved by the USFDA for muscle invasive bladder cancer

On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) to be used with gemcitabine and cisplatin as a first treatment, followed by durvalumab alone as a follow-...
pd-l1-inhibitor-for-mibc

Scan the code